Artivion, Inc.

NYSE:AORT Stock Report

Market Cap: US$995.9m

Artivion Past Earnings Performance

Past criteria checks 0/6

Artivion's earnings have been declining at an average annual rate of -13.4%, while the Medical Equipment industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 8.7% per year.

Key information

-13.4%

Earnings growth rate

-11.9%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate8.7%
Return on equity-4.8%
Net Margin-3.4%
Next Earnings Update05 May 2025

Recent past performance updates

Recent updates

Here's Why Artivion (NYSE:AORT) Has A Meaningful Debt Burden

Apr 08
Here's Why Artivion (NYSE:AORT) Has A Meaningful Debt Burden

Artivion, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

Feb 27
Artivion, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

Is Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)?

Feb 13
Is Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)?

Why Investors Shouldn't Be Surprised By Artivion, Inc.'s (NYSE:AORT) P/S

Jan 09
Why Investors Shouldn't Be Surprised By Artivion, Inc.'s (NYSE:AORT) P/S

Artivion: Current Valuation Seems Stretched.

Dec 26

Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)

Dec 19
Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)

When Should You Buy Artivion, Inc. (NYSE:AORT)?

Nov 07
When Should You Buy Artivion, Inc. (NYSE:AORT)?

Returns At Artivion (NYSE:AORT) Are On The Way Up

Sep 28
Returns At Artivion (NYSE:AORT) Are On The Way Up

Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Sep 06
Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Is Artivion (NYSE:AORT) A Risky Investment?

Jun 28
Is Artivion (NYSE:AORT) A Risky Investment?

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Jun 21

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 08
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jan 13
Is Artivion (NYSE:AORT) Using Too Much Debt?

Artivion Stock: A First Assessment

Dec 27

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Nov 23
Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Oct 13

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Jul 20

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 10
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Mar 09
Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Feb 16

Revenue & Expenses Breakdown

How Artivion makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:AORT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 24389-1319228
30 Sep 24385-119129
30 Jun 24377-818929
31 Mar 24368-1018828
31 Dec 23354-3118529
30 Sep 23340-2418029
30 Jun 23329-2817535
31 Mar 23320-2917136
31 Dec 22314-1916639
30 Sep 22314-4117040
30 Jun 22309-1716838
31 Mar 22305-1516338
31 Dec 21299-1516136
30 Sep 21287214533
30 Jun 21280-1214128
31 Mar 21258-1313526
31 Dec 20253-1713724
30 Sep 20255-1414323
30 Jun 20258-1114323
31 Mar 20275-514524
31 Dec 19276214323
30 Sep 19274214824
30 Jun 19271314023
31 Mar 19268114023
31 Dec 18263-314123
30 Sep 18248-512823
30 Jun 18227-512722
31 Mar 18207-211621
31 Dec 17190410119
30 Sep 17182910017
30 Jun 17183119616
31 Mar 17182109415
31 Dec 16180119213
30 Sep 16175107812
30 Jun 1616797611
31 Mar 1615577411
31 Dec 1514647210
30 Sep 1514337410
30 Jun 151443769
31 Mar 151436748
31 Dec 141457749
30 Sep 1414214729
30 Jun 1414115699

Quality Earnings: AORT is currently unprofitable.

Growing Profit Margin: AORT is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AORT is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.

Accelerating Growth: Unable to compare AORT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AORT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.1%).

Return on Equity

High ROE: AORT has a negative Return on Equity (-4.84%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/05 13:43
End of Day Share Price 2025/05/02 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Artivion, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Jason MillsCanaccord Genuity
Daniel StauderCitizens JMP Securities, LLC